- Home
- HLVX vs ELTX Comparison
HLVX vs ELTX Comparison
Compare HLVX & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- ELTX
- Stock Information
- Founded
- HLVX 2020
- ELTX 2011
- Country
- HLVX United States
- ELTX United States
- Employees
- HLVX N/A
- ELTX N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- HLVX Health Care
- ELTX Health Care
- Exchange
- HLVX Nasdaq
- ELTX Nasdaq
- Market Cap
- HLVX 104.3M
- ELTX 121.7M
- IPO Year
- HLVX 2022
- ELTX N/A
- Fundamental
- Price
- HLVX $2.09
- ELTX $11.47
- Analyst Decision
- HLVX Hold
- ELTX Strong Buy
- Analyst Count
- HLVX 1
- ELTX 2
- Target Price
- HLVX $2.00
- ELTX $11.00
- AVG Volume (30 Days)
- HLVX 862.9K
- ELTX 99.4K
- Earning Date
- HLVX 11-06-2025
- ELTX 11-12-2025
- Dividend Yield
- HLVX N/A
- ELTX N/A
- EPS Growth
- HLVX N/A
- ELTX N/A
- EPS
- HLVX N/A
- ELTX N/A
- Revenue
- HLVX N/A
- ELTX N/A
- Revenue This Year
- HLVX N/A
- ELTX N/A
- Revenue Next Year
- HLVX N/A
- ELTX N/A
- P/E Ratio
- HLVX N/A
- ELTX N/A
- Revenue Growth
- HLVX N/A
- ELTX N/A
- 52 Week Low
- HLVX $1.34
- ELTX $4.05
- 52 Week High
- HLVX $2.17
- ELTX $12.62
- Technical
- Relative Strength Index (RSI)
- HLVX 51.29
- ELTX 56.41
- Support Level
- HLVX $2.07
- ELTX $10.00
- Resistance Level
- HLVX $2.11
- ELTX $12.62
- Average True Range (ATR)
- HLVX 0.02
- ELTX 0.74
- MACD
- HLVX -0.00
- ELTX -0.04
- Stochastic Oscillator
- HLVX 50.00
- ELTX 55.92
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.